$BLAC
Bellevue Life Sciences Acquisition Corp.

2024 Q4 Form 10-Q Financial Statement

#000119312524258772 Filed on November 14, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3
Revenue $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $454.1K
YoY Change 10.65%
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $454.1K
YoY Change 10.65%
Operating Profit
YoY Change
Interest Expense $269.2K
YoY Change -56.48%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$184.9K
YoY Change -188.88%
Income Tax $46.03K
% Of Pretax Income
Net Earnings -$231.0K
YoY Change -395.41%
Net Earnings / Revenue
Basic Earnings Per Share -$0.06
Diluted Earnings Per Share -$0.06
COMMON SHARES
Basic Shares Outstanding 4.041M 4.041M
Diluted Shares Outstanding 4.041M

Balance Sheet

Concept 2024 Q4 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $12.24K
YoY Change -78.88%
Cash & Equivalents $12.24K
Short-Term Investments
Other Short-Term Assets $27.37K
YoY Change 11.9%
Inventory
Prepaid Expenses $27.37K
Receivables
Other Receivables
Total Short-Term Assets $39.61K
YoY Change -51.94%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $20.89M
YoY Change -71.01%
Other Assets
YoY Change
Total Long-Term Assets $20.89M
YoY Change -71.01%
TOTAL ASSETS
Total Short-Term Assets $39.61K
Total Long-Term Assets $20.89M
Total Assets $20.93M
YoY Change -70.99%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.259M
YoY Change 151.68%
Accrued Expenses $530.4K
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $1.778M
YoY Change 789.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $3.941M
YoY Change 256.62%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $3.941M
Total Long-Term Liabilities $0.00
Total Liabilities $6.011M
YoY Change 89.32%
SHAREHOLDERS EQUITY
Retained Earnings -$5.754M
YoY Change 134.37%
Common Stock $216.00
YoY Change 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$5.754M
YoY Change
Total Liabilities & Shareholders Equity $20.93M
YoY Change -70.99%

Cashflow Statement

Concept 2024 Q4 2024 Q3
OPERATING ACTIVITIES
Net Income -$231.0K
YoY Change -395.41%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$226.9K
YoY Change 58.41%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities -$150.0K
YoY Change -6100.0%
Cash From Investing Activities -$150.0K
YoY Change -6100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 270.0K
YoY Change 35.0%
NET CHANGE
Cash From Operating Activities -226.9K
Cash From Investing Activities -150.0K
Cash From Financing Activities 270.0K
Net Change In Cash -106.9K
YoY Change -288.24%
FREE CASH FLOW
Cash From Operating Activities -$226.9K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Entity Central Index Key
EntityCentralIndexKey
0001840425
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Address State Or Province
EntityAddressStateOrProvince
WA
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity Registrant Name
EntityRegistrantName
BELLEVUE LIFE SCIENCES ACQUISITION CORP.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity File Number
EntityFileNumber
001-41390
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
84-5052822
dei Entity Address Address Line1
EntityAddressAddressLine1
10900 NE 4th Street
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 2300
dei Entity Address City Or Town
EntityAddressCityOrTown
Bellevue
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
98004
dei City Area Code
CityAreaCode
425
dei Local Phone Number
LocalPhoneNumber
635-7700
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
true
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
4041221
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12236
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
15419
CY2024Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
27372
CY2023Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
7208
CY2024Q3 us-gaap Assets Current
AssetsCurrent
39608
CY2023Q4 us-gaap Assets Current
AssetsCurrent
22627
CY2024Q3 us-gaap Assets Held In Trust Noncurrent
AssetsHeldInTrustNoncurrent
20886019
CY2023Q4 us-gaap Assets Held In Trust Noncurrent
AssetsHeldInTrustNoncurrent
36605106
CY2024Q3 us-gaap Assets
Assets
20925627
CY2023Q4 us-gaap Assets
Assets
36627733
CY2024Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1259291
CY2023Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1081753
CY2024Q3 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
286367
CY2023Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
524562
CY2024Q3 us-gaap Sales And Excise Tax Payable Current
SalesAndExciseTaxPayableCurrent
530415
CY2023Q4 us-gaap Sales And Excise Tax Payable Current
SalesAndExciseTaxPayableCurrent
359957
CY2024Q3 us-gaap Notes Payable Current
NotesPayableCurrent
1778000
CY2023Q4 us-gaap Notes Payable Current
NotesPayableCurrent
0
CY2024Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
87000
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
72000
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
3941073
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2038272
CY2024Q3 blacu Deferred Underwriting Commissions
DeferredUnderwritingCommissions
2070000
CY2023Q4 blacu Deferred Underwriting Commissions
DeferredUnderwritingCommissions
2070000
CY2024Q3 us-gaap Liabilities
Liabilities
6011073
CY2023Q4 us-gaap Liabilities
Liabilities
4108272
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q3 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2155000
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2155000
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2155000
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2155000
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
216
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
216
CY2024Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
0
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
0
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-5754171
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-3907008
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
-5753955
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-3906792
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
20925627
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
36627733
CY2024Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
454132
CY2023Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
410431
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
1380457
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
968806
CY2024Q3 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-454132
CY2023Q3 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-410431
us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-1380457
us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-968806
CY2024Q3 us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
269204
CY2023Q3 us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
618499
us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
1215533
us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
1846529
CY2024Q3 us-gaap Other Income
OtherIncome
269204
CY2023Q3 us-gaap Other Income
OtherIncome
618499
us-gaap Other Income
OtherIncome
1215533
us-gaap Other Income
OtherIncome
1846529
CY2024Q3 us-gaap Income Loss Attributable To Parent
IncomeLossAttributableToParent
-184928
CY2023Q3 us-gaap Income Loss Attributable To Parent
IncomeLossAttributableToParent
208068
us-gaap Income Loss Attributable To Parent
IncomeLossAttributableToParent
-164924
us-gaap Income Loss Attributable To Parent
IncomeLossAttributableToParent
877723
CY2024Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
46033
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
129885
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
223762
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
387771
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-230961
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
78183
us-gaap Net Income Loss
NetIncomeLoss
-388686
us-gaap Net Income Loss
NetIncomeLoss
489952
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4041221
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
9055000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4866724
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7780824
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
4041221
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
9055000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
4866724
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7822857
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.06
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.01
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.08
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.06
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.06
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.01
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.08
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.03
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-3906792
CY2024Q1 blacu Accretion For Common Stock To Redemption Value
AccretionForCommonStockToRedemptionValue
-340351
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-60430
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-4307573
CY2024Q2 blacu Accretion For Common Stock To Redemption Value
AccretionForCommonStockToRedemptionValue
-328249
CY2024Q2 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
170458
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-97295
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-4903575
CY2024Q3 blacu Accretion For Common Stock To Redemption Value
AccretionForCommonStockToRedemptionValue
-619419
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-230961
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
-5753955
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-37508
CY2023Q1 us-gaap Stock And Warrants Issued During Period Value Preferred Stock And Warrants
StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants
1236527
CY2023Q1 blacu Accretion For Common Stock To Redemption Value
AccretionForCommonStockToRedemptionValue
-7439560
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
110305
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-1830236
CY2023Q2 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
-565737
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
301464
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-2094509
CY2023Q3 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
-438614
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
78183
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-2454940
us-gaap Profit Loss
ProfitLoss
-388686
us-gaap Profit Loss
ProfitLoss
489952
us-gaap Interest Income Interest Earning Asset Increase Decrease
InterestIncomeInterestEarningAssetIncreaseDecrease
1215533
us-gaap Interest Income Interest Earning Asset Increase Decrease
InterestIncomeInterestEarningAssetIncreaseDecrease
1846529
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
20164
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
24459
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
177538
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
453992
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
-238195
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
387771
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1685040
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-539273
blacu Proceeds From Trust Account For Payment To Redeeming Stockholders
ProceedsFromTrustAccountForPaymentToRedeemingStockholders
17045763
blacu Proceeds From Trust Account For Payment To Redeeming Stockholders
ProceedsFromTrustAccountForPaymentToRedeemingStockholders
0
us-gaap Payments To Acquire Restricted Investments
PaymentsToAcquireRestrictedInvestments
430000
us-gaap Payments To Acquire Restricted Investments
PaymentsToAcquireRestrictedInvestments
0
blacu Gain Loss From Trust Account To Pay Expenses
GainLossFromTrustAccountToPayExpenses
318857
blacu Gain Loss From Trust Account To Pay Expenses
GainLossFromTrustAccountToPayExpenses
0
blacu Cash Deposited In The Trust Account
CashDepositedInTheTrustAccount
0
blacu Cash Deposited In The Trust Account
CashDepositedInTheTrustAccount
70207500
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
16934620
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-70207500
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
17045763
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
0
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
0
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
59670000
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
1778000
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
0
us-gaap Payment Of Financing And Stock Issuance Costs
PaymentOfFinancingAndStockIssuanceCosts
0
us-gaap Payment Of Financing And Stock Issuance Costs
PaymentOfFinancingAndStockIssuanceCosts
1447273
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-15252763
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
70680227
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-3183
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-66546
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
15419
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
124501
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
12236
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
57955
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
461957
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0
us-gaap Payments For Underwriting Expense
PaymentsForUnderwritingExpense
0
us-gaap Payments For Underwriting Expense
PaymentsForUnderwritingExpense
2070000
CY2024Q3 blacu Condition For Future Business Combination Number Of Businesses Minimum
ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum
1
blacu Percentage Of Trust Account Required For Business Combination
PercentageOfTrustAccountRequiredForBusinessCombination
0.80
blacu Threshold Percentage Of Outstanding Voting Securities Of Target To Be Acquired By Post Transaction Company To Complete Business Combination
ThresholdPercentageOfOutstandingVotingSecuritiesOfTargetToBeAcquiredByPostTransactionCompanyToCompleteBusinessCombination
0.50
CY2024Q3 us-gaap Assets Held In Trust
AssetsHeldInTrust
70207500
us-gaap Debt Instrument Redemption Description
DebtInstrumentRedemptionDescription
The Company will provide its holders of the outstanding shares of its Common Stock sold in the Initial Public Offering (the “Public Stockholders”) with the opportunity to redeem all or a portion of their Public Shares upon the completion of a Business Combination either (i) in connection with a stockholder meeting called to approve the Business Combination or (ii) by means of a tender offer. The decision as to whether the Company will seek stockholder approval of a Business Combination or conduct a tender offer will be made by the Company, solely in its discretion. The Public Stockholders will be entitled to redeem their Public Shares (as described in Note 1) for a pro rata portion of the amount then in the Trust Account (initially anticipated to be $10.175 per Public Share plus any pro rata interest then in the Trust Account, net of taxes payable). The per share amount to be distributed to Public Stockholders who redeem their Public Shares will not be reduced by the deferred underwriting commissions the Company will pay to the underwriters (as discussed in Note 5).
blacu Redemption Limit Percentage
RedemptionLimitPercentage
0.15
blacu Percentage Obligation To Redeem Public Shares If Entity Does Not Complete Business Combination
PercentageObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination
1
blacu Period To Consummate Business Combination
PeriodToConsummateBusinessCombination
P9M
blacu Percentage Obligation To Redeem Public Shares If Entity Does Not Complete Business Combination
PercentageObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination
1
blacu Maximum Allowed Dissolution Expenses
MaximumAllowedDissolutionExpenses
100000
CY2024Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3432046
CY2024Q1 us-gaap Temporary Equity Redemption Price Per Share
TemporaryEquityRedemptionPricePerShare
10.49
CY2024Q1 us-gaap Temporary Equity Value Excluding Additional Paid In Capital
TemporaryEquityValueExcludingAdditionalPaidInCapital
35995728
CY2024Q1 us-gaap Common Stock Value Outstanding
CommonStockValueOutstanding
36372335
CY2024Q1 blacu Interest Income Held In The Trust Account
InterestIncomeHeldInTheTrustAccount
561957
CY2023Q4 blacu Investment Of Cash In Trust Account
InvestmentOfCashInTrustAccount
180000
CY2024Q1 blacu Cash Deposited In The Trust Account
CashDepositedInTheTrustAccount
60000
CY2024Q2 blacu Cash Deposited In The Trust Account
CashDepositedInTheTrustAccount
60000
CY2024Q1 blacu Cash Deposited In The Trust Account
CashDepositedInTheTrustAccount
60000
CY2024Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1581733
CY2024Q4 us-gaap Temporary Equity Redemption Price Per Share
TemporaryEquityRedemptionPricePerShare
10.78
CY2024Q4 us-gaap Temporary Equity Value Excluding Additional Paid In Capital
TemporaryEquityValueExcludingAdditionalPaidInCapital
17045763
CY2024Q4 us-gaap Common Stock Value Outstanding
CommonStockValueOutstanding
20327120
blacu Interest Income Held In The Trust Account
InterestIncomeHeldInTheTrustAccount
218857
CY2024Q2 blacu Cash Deposited In The Trust Account
CashDepositedInTheTrustAccount
50000
CY2024Q3 blacu Cash Deposited In The Trust Account
CashDepositedInTheTrustAccount
50000
CY2024Q3 blacu Cash Deposited In The Trust Account
CashDepositedInTheTrustAccount
50000
CY2024Q3 blacu Cash Deposited In The Trust Account
CashDepositedInTheTrustAccount
50000
CY2024Q4 blacu Cash Deposited In The Trust Account
CashDepositedInTheTrustAccount
50000
CY2024Q2 blacu Cash Deposited In The Trust Account
CashDepositedInTheTrustAccount
50000
CY2023Q4 blacu Interest Income Held In The Trust Account
InterestIncomeHeldInTheTrustAccount
561957
CY2024Q2 us-gaap Income Taxes Paid
IncomeTaxesPaid
461957
CY2024Q2 blacu Interest Income Held In The Trust Account
InterestIncomeHeldInTheTrustAccount
100000
CY2024Q2 blacu Interest Income Held In The Trust Account
InterestIncomeHeldInTheTrustAccount
218857
blacu Interest Income Held In The Trust Account
InterestIncomeHeldInTheTrustAccount
880814
blacu Withdrawal Of Income Held In Trust Account
WithdrawalOfIncomeHeldInTrustAccount
225674
CY2024Q3 us-gaap Cash
Cash
12236
CY2024Q3 us-gaap Debt Current
DebtCurrent
3901465
us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Use of Estimates </div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The preparation of financial statements in conformity with GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the financial statements and the reported amounts of expenses during the reporting periods. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effects of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates. </div>
CY2024Q3 us-gaap Cash
Cash
12236
CY2023Q4 us-gaap Cash
Cash
15419
CY2023Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0
CY2024Q3 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Concentration of Credit Risk </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution, which, at times, may exceed the Federal Deposit Insurance Corporation coverage of $250,000. Any loss incurred or a lack of access to such funds could have a significant adverse impact on the Company’s financial condition, results of operations, and cash flows. </div>
us-gaap Concentration Risk Credit Risk Financial Instrument Maximum Exposure
ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure
250000
blacu Number Of Shares Issued Per Unit
NumberOfSharesIssuedPerUnit
1
CY2024Q3 blacu Common Stock Shares Excluded From Calculation Of Net Income Loss Per Share
CommonStockSharesExcludedFromCalculationOfNetIncomeLossPerShare
7330000
CY2023Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2024Q3 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2023Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued
0
CY2024Q3 us-gaap Unrecognized Tax Benefits Income Tax Penalties Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued
0
CY2024Q3 blacu Maximum Number Of Demands For Registration Of Securities
MaximumNumberOfDemandsForRegistrationOfSecurities
2
blacu Effective Excise Tax Rate
EffectiveExciseTaxRate
1
blacu Effective Excise Tax Rate
EffectiveExciseTaxRate
1
CY2024Q3 us-gaap Sales And Excise Tax Payable Current
SalesAndExciseTaxPayableCurrent
530415
CY2023Q4 us-gaap Sales And Excise Tax Payable Current
SalesAndExciseTaxPayableCurrent
359957
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
us-gaap Common Stock Voting Rights
CommonStockVotingRights
Common stockholders of record are entitled to one vote for each share held on all matters to be voted on by stockholders.
CY2023Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
7330000
CY2024Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
7330000
CY2024Q3 us-gaap Assets Held In Trust Noncurrent
AssetsHeldInTrustNoncurrent
20886019
CY2023Q4 us-gaap Assets Held In Trust Noncurrent
AssetsHeldInTrustNoncurrent
36605106
CY2023 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
0
CY2024Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001193125-24-258772-index-headers.html Edgar Link pending
0001193125-24-258772-index.html Edgar Link pending
0001193125-24-258772.txt Edgar Link pending
0001193125-24-258772-xbrl.zip Edgar Link pending
blacu-20240930.xsd Edgar Link pending
d865272d10q.htm Edgar Link pending
d865272dex311.htm Edgar Link pending
d865272dex312.htm Edgar Link pending
d865272dex321.htm Edgar Link pending
d865272dex322.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
blacu-20240930_cal.xml Edgar Link unprocessable
blacu-20240930_def.xml Edgar Link unprocessable
blacu-20240930_lab.xml Edgar Link unprocessable
blacu-20240930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
d865272d10q_htm.xml Edgar Link completed
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending